Abstracts Archive - Page 201 of 2607 - ACR Meeting Abstracts

Abstract Number: 2618 • ACR Convergence 2024
Population Health Management for Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Danielle Bullock⁷, Jon Burnham⁸, Tzielan Lee⁹, Daniel Lovell¹⁰, Ted Wimmel¹¹, Delores Mincarelli¹¹, Mayur Patil¹², Magen Phillips¹¹ and Esi Morgan¹³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷M Health Fairview Masonic Children’s Hospital, Minneapolis, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Hive Networks, Newport, ¹²VSquare Infotech Inc, Edison, NJ, ¹³Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning health network with a vision that children with rheumatic disease will have…
Abstract Number: 2692 • ACR Convergence 2024
Transcriptomic Profiling of Kidney Biopsies Implicates Th17 and IL-17 in ANCA-Associated Vasculitis
Ivana Stojkic¹, Arnon Arazi², Huijuan Song³, Pearlly Yan⁴, Estela Puchulu-Campanella³, Hubao Wang³, Lynn Fussner³, Brad Rovin³, Samir Parikh⁵, Stacy Ardoin⁶, Daniel Koboldt⁷, James Fitch⁷ and Salem Almaani⁸, ¹Nationwide, Columbus, OH, ²Feinstein Institutes for Medical Research, Melrose, MA, ³The Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, ⁵Ohio State University, Columbus, OH, ⁶Nationwide Children's Hospital, Columbus, OH, ⁷Steve and Cindy Rasmussen Institute for Genomic Medicine, Columbus, OH, ⁸The Ohio State University Medical Center, Columbus, OH
Background/Purpose: ANCA-associated vasculitis (AAV) is a severe autoimmune disease targeting small vessels, with significant kidney involvement. Despite current therapies, up to 28% of patients progress…
Abstract Number: 2499 • ACR Convergence 2024
Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease shock syndrome (KDSS) is a phenotype of Kawasaki disease (KD) associated with higher rates of refractory KD (RKD) and coronary artery aneurysms…
Abstract Number: 2519 • ACR Convergence 2024
What Do We Know About Malignancies in IgA Vasculitis?
Alojzija Hocevar¹, Jaka Ostrovrsnik², vesna Jurcic³ and Ziga Rotar⁴, ¹University Medical Center Ljubljana, LJUBLJANA, Slovenia, ²UMC Ljubljana, Dpt. of Rheumatology, Ljubljana, Slovenia, ³Medical Faculty, University of Ljubljana, Institute of pathology, Ljubljana, Slovenia, ⁴University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Cancer has been reported as a potential trigger of IgA vasculitis (IgAV) in adults, however data on this topic is scarce. The aim of…
Abstract Number: PP09 • ACR Convergence 2024
Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS
Robert Fearon, Sjögren's Foundation, Reston, VA
Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…
Abstract Number: 2628 • ACR Convergence 2024
Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study
James Bistolarides¹, Vidya Sivaraman², Else Bosman³, Linda Wagner-Weiner⁴, Kimberly Morishita⁵, James Nocton¹, Melodee Liegl¹, Amy Pan¹ and David Cabral⁶, and PedVas Investigators Network, ¹Medical College of Wisconsin, Milwaukee, WI, ²Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ³UBC, Vancouver, BC, Canada, ⁴University of Chicago, Chicago, IL, ⁵University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…
Abstract Number: 2529 • ACR Convergence 2024
Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project
Dori Abel¹, Kirsten Spichiger², Megan Roman², William Baar², Claire O'Malley², Jay Mehta¹, Terri Al'Hadi², Kerry Ferraro³, Denique Butler², Asia Wilson-Sanders², Catherine Lewis², Danielle Dodson⁴ and Jon Burnham¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Although new therapeutics and treat-to-target interventions have improved JIA care, pronounced racial and ethnic outcome disparities persist. At our center, the mean population-level clinical Juvenile…
Abstract Number: PP02 • ACR Convergence 2024
Living Well with a Rare Rheumatic Disease – Becoming a “Precision” Patient on the Horizon of Precision Medicine
Ida Hakkarinen, self, Greenbelt, MD
Background/Purpose: My journey with a rare, chronic, relapsing rheumatic disease began in November 2010 with a variety of seemingly unrelated symptoms: migrating joint pain, night…
Abstract Number: 2525 • ACR Convergence 2024
Challenges and Opportunities in Integrating Sleep Recommendations into Counselling Patients with Arthritis: A Survey of Physical Therapists and Physical Therapy Students
Codie Primeau¹, Deniz Bayraktar², Michelle Kho³, Christopher Tong⁴ and Linda Li¹, ¹Arthritis Research Canada & University of British Columbia, Vancouver, BC, Canada, ²Izmir Katip Celebi University, Izmir, Turkey, ³McMaster University, Hamilton, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Individuals with arthritis face challenges in balancing activity, rest, and sleep. While physical therapists address activity, sleep considerations are often overlooked, despite evidence suggesting…
Abstract Number: 2653 • ACR Convergence 2024
Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis
Elaine Yung¹, Xiaoxuan Liu², Bin Huang³, Michael Wagner¹, Minal Aundhia², Chen Chen⁴ and hermine brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, ³Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cin, OH, ⁵Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: When uncontrolled, JIA is associated with short-term and long-term complications that affect the patient’s quality of life. A common goal of treatment is to…
Abstract Number: 2665 • ACR Convergence 2024
Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima¹, Atsubumi Ogawa², Motohiro Nonaka², Norimichi Nomura², Yasuhiro Nohda², Mirei Shirakashi³, Ryosuke Hiwa², Hideaki Tsuji¹, Shuji Akizuki⁴, Hajime Yoshifuji¹, Tsuneyo Mimori⁵ and Akio Morinobu⁶, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Kyoto University, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁵Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD), leading to poor prognosis. Initial combinational therapy…
Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta DeGuzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…
Abstract Number: 2493 • ACR Convergence 2024
Mortality in Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: Study from a Single University Hospital
Fabricio Benavides¹, Alba Herrero-Morant², Diana Prieto-Peña³, Vanesa Calvo-Rio⁴, Salma Al Fazazi⁵, Adrián Martín-Gutiérrez⁶, Mónica Renuncio-García⁷, Amparo Sánchez-López⁸, Claudia Poo-fernandez⁸, Clara Escagedo-Cagigas⁸, Maria Rodríguez-Vidriales¹ and Ricardo Blanco-Alonso⁹, ¹Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Ontinyent, Cantabria, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ⁴Valdecilla Hospital, Santander, Cantabria, Spain, ⁵Hospital Universitario Virgen de la Victoria, Málaga, Andalucia, Spain, ⁶Hospital Universitario Marques de Valdecilla, IDIVAL, Renedo de Piélagos, Cantabria, Spain, ⁷Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁸Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) includes Granulomatosis with polyangiitis (GPA), Microscopic polyarteritis (MPA) and Eosinophilic granulomatosis with polyangiitis (EGPA). Due to clinical,…
Abstract Number: 2520 • ACR Convergence 2024
Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019
Peter Merkel¹, Yi Peng², Patrick Zueger², Clara Ziadeh³, Ana B. Romero⁴, Richard Thielen³ and Denise Kruzikas³, ¹Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, ²AbbVie Inc, North Chicago, IL, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, North Chicago, IL
Background/Purpose: Giant cell arteritis (GCA) is a vasculitis affecting individuals aged ≥50 years. Over 80% of patients with GCA are aged ≥70 years, reflecting a…
Abstract Number: 2527 • ACR Convergence 2024
Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
Jacques-Eric Gottenberg¹, Kathy Sivils², Kim Campbell³, Jada Idokogi³, Kim Lo³, Sophia G. Liva³, Jonathan Shelton⁴, Harman Dhatt⁵, Jonathan J. Hubbard³ and Ghaith Noaiseh⁶, ¹Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ²Johnson & Johnson Innovative Medicine, Edmond, OK, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Janssen Scientific Affairs, LLC, San Diego, CA, USA, San Diego, ⁵Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, USA, Raritan, NJ, ⁶University of Kansas Medical Center, Kansas City, KS
Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by the presence of specific autoantibodies (AAb) and lymphocytic infiltration of exocrine glandular tissues.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].